Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
  • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• New amino derivatives of 2 ", 3" dideoxygiycosides of epipodophyllotoxin, their preparation process, their use as a medicament and their use intended for anticancer treatments.
• the present invention relates to new amino derivatives 2 ", 3" dideoxygiycosides of epipodophyllotoxin, their preparation process, their use as a medicament and their use intended for anticancer treatments.
• epipodophylloids having the basic skeleton of podophyllotoxin. It includes hemi-synthetic derivatives such as Etoposide or Teniposide which are commonly used in the preparation of drugs for the treatment of cancer. They are considered major products in this area.
• Etoposide has anti-tumor properties and is used to treat in particular small cell lung cancer and testicular cancer.
• the object of the present invention is to show that derivatives of 4'-demethyl epipodophyllotoxin, having in position 4, a substitution of structure 2 "-deoxyglycoside, allows, by the incorporation of one or more nitrogen, to form compounds whose addition salts have an aqueous solubility which makes it possible to respond to the problem and show the desired anticancer activity.
• Patent EP-0 196 618 relates to water-soluble derivatives of 4'-demethyl epipodophyllotoxin of formula:
• R 1 and R 2 identical or different represent a hydrogen atom, a C 1 to C 6 alkyl group, which can form a ring, this ring possibly comprising a heteroatom such as oxygen or nitrogen, a C 1 to C 6 aminoalkyl group or cyanomethyl.
• X and Y can be the same or different and represent an OH, CH 3 , CH 2 - NH 2 , X and Y can also be linked and form a ring, such as, for example, 2-methyl 1,3 dioxane, thus forming a 4,2-ethylidene 3-amino-2,3-dideoxy- ⁇ -D arabino or ribo-hexo pyranoside type bicyclic osidic skeleton.
• the NR 1 R 2 group is an NH 2 or N (CH 3 ) 2 group .
• the NR 1 R 2 group can also be an amino group substituted once or twice with methyl, CH 2 CN, CH 2 -CH 2 -NH 2 , forming a ring such as morpholine.
• the compounds of general formula I will be chosen with a glycoside for which X and Y form a ring with a chain OCH (CH 3 ) OCH 2 , such as 4,6 ethylidene-3-amino-2,3 -dideoxy- ⁇ -D arabino-hexo pyranoside or else 4.6 ethylidene-3-amino-2,3-de ⁇ oxy- ⁇ -D-ribo-hexopyranoside.
• the compounds according to the invention are selected from the following compounds:
• the present invention also relates to pharmaceutical compositions comprising at least one compound of general formula I according to the invention and an appropriate excipient.
• compositions can be presented in a suitable manner by administration by the injectable route or by the oral route in the form of capsules, capsules, tablets at the dosage of 1 to 200 mg / m 2 by injection and from 5 to 500 mg. / m 2 orally per 24 h period.
• These derivatives can thus be administered in human clinic to treat different forms of cancer such as small cell lung cancer, testicular cancer, embryonic tumors, neuroblastomas, kidney cancer, Hodgkin's and non-Hodgkin's lyphomas, acute leukemias, colorectal cancers, melanomas, placental choriocarcinomas and breast adenocarcinomas.
• cancer such as small cell lung cancer, testicular cancer, embryonic tumors, neuroblastomas, kidney cancer, Hodgkin's and non-Hodgkin's lyphomas, acute leukemias, colorectal cancers, melanomas, placental choriocarcinomas and breast adenocarcinomas.
• the present invention also relates to processes for the preparation of the compounds of formula I as well as their addition salts with pharmaceutically acceptable mineral or organic acids.
• the present invention therefore relates to the processes for preparing the compounds of general formula I according to the invention, in which a compound of formula III or IV or V is reacted
• the substituent in position 3 can be ⁇ or ⁇
• NR 1 R 2 can be an amino protected by a group Z
• P represents an alcohol protecting group and the products resulting from this condensation are deprotected and hydrogenated to provide the compounds of formula I,
• the primary amines in position 3 of the glycosyl are methylated by formalin and sodium cyanoborohydride.
• the intermediate of formula IV is prepared by reacting a mixture of diacetoxy azido glycoside VI
• glycosidic intermediate azide ⁇ 12 follows the same reaction sequence as its epimer and provides in an identical manner the coupling derivative with DMEPT4'OZ from the azide 3 " ⁇ 13, in this case the coupling is carried out more easily according to two techniques.
• the first technique consists in treating the ribohexopyranoside derivative 13 with trimethyl silyl trifluoromethane sulfonate (TMSOTf) at - 40 ° C in CH 2 Cl 2 .
• TMSOTf trimethyl silyl trifluoromethane sulfonate
• the second technique consists in using the etherate of BF 3 in CH 2 Cl 2 at - 15 ° C.
• the silylated ⁇ azide 12 is selectively tosylated with tosyl chloride in pyridine at 21, the primary alcohol tosylate is exchanged for iodo derivative 22.
• the secondary alcohol in position 4 is protected by a chloroacetate to provide the functionalized 2-desoxysugre 23 ready to be condensed with DMEPT 4'-OZ under the usual conditions with the etherate of BF 3 in methylene chloride at low temperature.
• the salts formed from the nitrogen compounds are, for example, hydrochlorides and are formed conventionally by treating a methanolic solution of the nitrogen compound with a stoichiometric solution with respect to sites to be salified with hydrochloric methanol previously dosed
• the crystallized hydrochloride can optionally be obtained by precipitation in the reaction medium by addition of ethyl ether.
• aqueous phase is extracted with CH 2 Cl 2 (200 ml) then after drying over MgSO 4 , the organic phase is concentrated under reduced pressure and the residue (18.7 g) is chromatographed on silica gel (cyclohexane / AcOEt: 9/1). 10.7 g of 3 (syrup; 48%) and 4.7 g of 4 (syrup; 21%) are thus isolated; however, intermediate fractions contain a mixture of 3 and 4 (3.3 g; 15%).
• reaction medium After stirring for 8 h, the reaction medium is poured into 100 ml H 2 O and the aqueous phase is extracted with CH 2 C1 2 (100 ml). The organic phase is dried over MgSO 4 , concentrated under reduced pressure and the residue is purified by chromatography on silica gel (cyclohexane / AcOEt: 6/1 and 4/1) in order to isolate 1.9 g of 8 (72% ).
• reaction medium After reaction for 5 h at 20 ° C, the reaction medium is filtered and then concentrated under reduced pressure to provide 59 mg of pure 28 (94%).
• the molecules have been tested in biological experiments and have shown their interest as an anticancer agent in tests for P 388 leukemia in vivo in mice. This test is commonly used in the field of anti-cancer substances research (Protocols for screening chemical agents and natural products against animal tumors and other biological Systems, R. Geran, NH Greenberg, MM MacDonald, AM Schumacher and BJ Abbott, Cancer Chemotherapy reports 1972, 3, No. 2).
• ED 50 the effective dose 50 which represents the single minimum dose of the compound to be administered in order to obtain significant animal survival compared to the untreated control animals
• P 388 leukemia was chemically induced in 1955 by 3-methylcholanthrene in a DBA / 2 mouse (Am. J. Pathol. 33, 603, 1957).
• the tumors are maintained by weekly passages in the form of ascites in the peritoneum of DBA / 2 mice (original line) and the experiments are carried out on CDF ⁇ hybrid female mice (bal b / c female XDBA / 2 males) of 20 ⁇ 2 g (Cancer chemother. Rep. 3, 9, 1972).
• the tumor cells are implanted intravenously (106 cells per mouse) on day 0.
• the animals are randomized and divided into groups of 2 for each series.
• Anti-tumor substances are administered intraperitoneally (ip) one day after inoculation of the leukemia cells (acute treatment).
• the solutions are injected at the rate of 10 ml / kg of mouse.
• the criterion for evaluating anti-tumor activity is the prolongation of the survival of the animals treated. 86% of the mice die on the 7th day after the tumor transplant. A substance will be considered active if it induces survival longer than 8 days.
• the compounds of the invention have retained the level of activity of the reference compounds such as Etoposide and have the additional advantage of having an aqueous solubility which is advantageous for formulation and administration.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Biochemistry (AREA)
• Biotechnology (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Saccharide Compounds (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=9483465

Family Applications (1)

Country Status (10)

Families Citing this family (7)

Family Cites Families (2)

• 1995
  • 1995-10-12 FR FR9511978A patent/FR2739857B1/fr not_active Expired - Fee Related
• 1996
  • 1996-10-11 BR BR9610851A patent/BR9610851A/pt not_active Application Discontinuation
  • 1996-10-11 EP EP96934895A patent/EP0873347A2/fr not_active Withdrawn
  • 1996-10-11 KR KR1019980702647A patent/KR19990064166A/ko not_active Application Discontinuation
  • 1996-10-11 WO PCT/FR1996/001588 patent/WO1997013776A2/fr not_active Application Discontinuation
  • 1996-10-11 CN CN96198199A patent/CN1202173A/zh active Pending
  • 1996-10-11 JP JP9514777A patent/JP2000505053A/ja active Pending
  • 1996-10-11 CA CA002234484A patent/CA2234484A1/fr not_active Abandoned
  • 1996-10-11 NZ NZ320323A patent/NZ320323A/xx unknown
  • 1996-10-11 AU AU73040/96A patent/AU7304096A/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events